This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, Vladimir,
Salloway, Stephen,
van Dyck, Christopher H.,
Dubois, Bruno,
Andreasen, Niels,
Brody, Mark,
Curtis, Craig,
Soininen, Hilkka,
Thein, Stephen,
Shiovitz, Thomas,
Pilcher, Gary,
Ferris, Steven,
Colby, Susan,
Kerselaers, Wendy,
Dockens, Randy,
Soares, Holly,
Kaplita, Stephen,
Luo, Feng,
Pachai, Chahin,
Bracoud, Luc,
Mintun, Mark,
Grill, Joshua D.,
Marek, Ken,
Seibyl, John,
Cedarbaum, Jesse M.,
Albright, Charles,
Feldman, Howard H.,
Berman, Robert M.
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study
Mild cognitive impairment (MCI) in Parkinson’s disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal […]
Longitudinal medication usage in Alzheimer disease patients
Zhu, Carolyn W.,
Livote, Elayne E.,
Kahle-Wrobleski, Kristin,
Scarmeas, Nikolaos,
Albert, Marilyn,
Brandt, Jason,
Blacker, Deborah,
Sano, Mary,
Stern, Yaakov
This study examined in detail patterns of cholinesterase inhibitors (ChEIs) and memantine use and explored the relationship between patient characteristics and such use. Patients with probable Alzheimer disease AD (n=201) were recruited from the Predictors Study in 3 academic AD centers and followed from early disease stages for up to 6 years. Random effects logistic […]
Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: A pilot study
Wong, G. K. C.,
Wong, R.,
Mok, V.,
Wong, A.,
Fan, D.,
Leung, G.,
Chan, A.,
Poon, W. S.
Background and objective: Rivastigmine has been shown to be effective for patients with mild-to-moderate Alzheimer’s disease. Its effect on cognitive impairment after aneurysmal subarachnoid haemorrhage has not been previously studied. The aim of the study is to evaluate the efficacy and safety of rivastigmine 3 mg day over 12 weeks in patients with aneurysmal subarachnoid […]
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Schmitt, Frederick A.,
Aarsland, Dag,
Brønnick, Kolbjørn S.,
Meng, Xiangyi,
Tekin, Sibel,
Olin, Jason T.
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]
How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist
Sakakibara, Ryuji,
Ogata, Takeshi,
Uchiyama, Tomoyuki,
Kishi, Masahiko,
Ogawa, Emina,
Isaka, Shigeo,
Yuasa, Joji,
Yamamoto, Tatsuya,
Ito, Takashi,
Yamanishi, Tomonori,
Awa, Yusuke,
Yamaguchi, Chiharu,
Takahashi, Osamu
Although urinary incontinence inevitably occurs in advanced stages of dementia of any etiology, urinary urgency or frequency, also called an overactive bladder (OAB), occurs more commonly in dementia with Lewy bodies (DLB) and vascular dementia than it does in Alzheimer’s disease (AD). Acetylcholinesterase (AChE) inhibitors for dementia and anticholinergics for OAB have been widely used, […]
No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease
Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]